SKB264 Plus Glecirasib in Advanced KRAS G12C-Mutant NSCLC: A Phase II Study

NCT07670013 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
43
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Second Affiliated Hospital, Zhejiang University, School of Medicine

Collaborators